Lsv Asset Management Puma Biotechnology, Inc. Transaction History
Lsv Asset Management
- $41.9 Billion
- Q2 2025
A detailed history of Lsv Asset Management transactions in Puma Biotechnology, Inc. stock. As of the latest transaction made, Lsv Asset Management holds 535,740 shares of PBYI stock, worth $2.61 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
535,740
Previous 53,400
903.26%
Holding current value
$2.61 Million
Previous $158,000
1062.66%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding PBYI
# of Institutions
124Shares Held
33.3MCall Options Held
68.2KPut Options Held
0-
Acorn Capital Advisors, LLC New York, NY4.13MShares$20.1 Million9.27% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.71MShares$18.1 Million0.0% of portfolio
-
Black Rock Inc. New York, NY3.57MShares$17.4 Million0.0% of portfolio
-
Acadian Asset Management LLC Boston, MA2.01MShares$9.78 Million0.01% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny1.87MShares$9.13 Million0.01% of portfolio
About PUMA BIOTECHNOLOGY, INC.
- Ticker PBYI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,556,000
- Market Cap $222M
- Description
- Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for...